Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KRTX | Common Stock | Tax liability | -$88.4K | -278 | -1.3% | $318.00 | 21.2K | Feb 13, 2024 | Direct | F1 |
Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Underlying Class | Amount | Exercise Price | Ownership | Footnotes |
---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
transaction | KRTX | Restricted Stock Units | Award | $0 | +10.3K | $0.00 | 10.3K | Feb 13, 2024 | Common Stock | 10.3K | Direct | F2 |
Id | Content |
---|---|
F1 | Represents shares withheld by the Issuer to satisfy tax withholding obligations in connection with the partial vesting of restricted stock units ("RSUs") previously granted to the Reporting Person on February 13, 2023. |
F2 | Reflects the annual equity award to the reporting person under the Karuna Therapeutics, Inc. 2019 Stock Option and Incentive Plan. Each RSU represents a contingent right to receive one share of the Issuer's common stock, provided that, at the effective time of the proposed merger transaction among the Issuer, Bristol-Myers Squibb Company and Miramar Merger Sub Inc., this RSU award will convert into a cash award equal to the product of (i) the total number of shares of the Issuer's common stock subject to this RSU award immediately prior to such effective time, and (ii) $330. The RSUs or, after such conversion, the cash award, shall vest annually in four equal installments on each of February 13, 2025, February 13, 2026, February 13, 2027 and February 13, 2028, subject to the reporting person's continued service through each such vesting date. |